Akinbolade, S, Coughlan, D, Fairbairn, R et al. (4 more authors) (2022) Combination therapies for COVID‐19: An overview of the clinical trials landscape. British Journal of Clinical Pharmacology, 88 (4). pp. 1590-1597. ISSN 0306-5251
Abstract
The COVID-19 pandemic has driven an unprecedented level of global activity in drug discovery and clinical development for effective therapeutics targeting the coronavirus disease. There are currently 744 therapeutics being tested in 2879 clinical trials globally. Almost 90% of these clinical trials are focused on monotherapies. Combination therapies are the mainstay of antiviral therapeutics to increase the potency of the individual compounds and to combat the rapid evolution of resistance, although combination therapies have inherently complex clinical and regulatory development challenges. Increased understanding of the SARS-CoV-2 lifecycle and COVID-19 pathology provides a scientific rationale for evaluating the effectiveness of different combinations. In this paper, we provide an overview of the current clinical trial landscape for combination therapeutics targeting COVID-19 through weekly scanning of national and international clinical trial registries. Our analysis delves specifically into dual combination therapies in what can be defined as “pivotal clinical trials” (active, randomised, controlled and at least phase II), with a focus on new and repurposed therapeutic candidates that have shown positive signals and/or been granted authorisation for emergency use based on positive efficacy and safety data.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 British Pharmacological Society. This is the peer reviewed version of the following article :Akinbolade, S, Coughlan, D, Fairbairn, R et al. (4 more authors) (2022) Combination therapies for COVID‐19: An overview of the clinical trials landscape. British Journal of Clinical Pharmacology, 88 (4). pp. 1590-1597, which has been published in final form at https://doi.org/10.1111/bcp.15089. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited. |
Keywords: | clinical trials; combination therapy; COVID-19; pivotal trials; SARS-CoV-2; treatment |
Dates: |
|
Institution: | The University of Leeds |
Academic Units: | The University of Leeds > Faculty of Biological Sciences (Leeds) > School of Biology (Leeds) |
Depositing User: | Symplectic Publications |
Date Deposited: | 08 Dec 2021 10:29 |
Last Modified: | 23 Sep 2022 00:16 |
Status: | Published |
Publisher: | Wiley |
Identification Number: | 10.1111/bcp.15089 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:181175 |